Homo sapiens protein kinase C, beta (PRKCB), transcript variant 2
Synonyms:
PKC-beta; PKCB; PRKCB1; PRKCB2
Immunogen
A phospho specific peptide corresponding to residues surrounding serine 660 of human PKC?II was used as an immunogen. This antibody detects PKC?II phosphorylated at serine 660.
Buffer
50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
PKC?II is a member of the serine/threonine protein kinase C (PKC) family (1) that includes 10 closely related isozymes classified as the conventional, the novel and the atypical. The conventional PKC?II is implicated in diverse cellular process including secretion, proliferation, differentiation, apoptosis, permeability, migration & hypertrophy (2-3). PKC?II structure consists of a C-terminal catalytic region, containing an activator-binding domain and a Ca2+-binding domain, and a regulatory domain. It has been shown that PKC?II must first be processed by three distinct phosphorylations before it is competent to respond to second messengers. Specifically, the threonine at position 500 (T500) on the activation loop, and T641 and S660 on the carboxyl terminus of protein kinase C beta II are phosphorylated in vivo. T500 and S660 are selectively dephosphorylated in vitro by protein phosphatase 2A to yield an enzyme that is still capable of lipid-dependent activation, whereas all three residues are dephosphorylated by protein phosphatase 1 to yield an inactive enzyme. (4).
Related Pathway
EGFR1 Signaling Pathway
Focal Adhesion
Hemostasis
MAPK signaling pathway
Melanogenesis
TGF Beta Signaling Pathway
Wnt Signaling Pathway
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Western blot analysis on Jurkat cell lysates using anti-Phospho- PKCβII (pS660), 1:100,000 dilution. Cells were either (A) untreated (B) treated with AP.
